Stock listing
CSE:OPTI Optimi Health Corp. Stock
Home listing (CSE) of Optimi Health Corp.
Follow Optimi Health Corp. into a list and get an email when it puts out news.
Share price · CSE:OPTI
$2.30 CAD -0.31 (-11.9%)
Close on Nov 20, 2026
- Day range
- $2.25 – $2.61 CADNov 20, 2026
- Volume
- 7,334 sharesNov 20, 2026
- Market cap
- $13.17M CADAt the close on Nov 20, 2026 · price × 5.73M shares outstanding
- 52-week range
- $2.25 – $12.15 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $25,481 CADMedian day 4,080 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:OPTI · Home | $2.30 CAD | -0.31 (-11.9%) | 7,334 | $2.61 | $2.61 | $2.25 | $2.61 | Close on Nov 20, 2026 |
| NASDAQ:OPTH | $1.51 USD | -0.24 (-13.7%) | 26,030 | $1.73 | $1.85 | $1.51 | $1.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:OPTI · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.30 | -0.31 | -11.9% | $2.61 | $2.61 | $2.25 | 7,334 | |
| $2.61 | -0.39 | -13.0% | $3.00 | $3.00 | $2.61 | 4,135 | |
| $3.00 | -0.10 | -3.2% | $3.10 | $3.14 | $2.80 | 3,354 | |
| $3.10 | -0.10 | -3.1% | $3.20 | $3.27 | $2.95 | 15,500 | |
| $3.20 | +0.06 | +1.9% | $3.13 | $3.29 | $3.00 | 10,146 | |
| $3.14 | -0.26 | -7.6% | $3.40 | $3.40 | $3.10 | 6,692 | |
| $3.40 | +0.17 | +5.3% | $3.30 | $3.40 | $3.09 | 4,005 | |
| $3.23 | -0.27 | -7.7% | $3.63 | $3.63 | $3.23 | 11,123 | |
| $3.50 | +0.23 | +7.0% | $3.30 | $3.60 | $3.15 | 8,462 | |
| $3.27 | +0.14 | +4.5% | $3.30 | $3.36 | $3.27 | 1,289 | |
| $3.13 | +0.07 | +2.3% | $3.15 | $3.26 | $2.99 | 13,651 | |
| $3.06 | +0.11 | +3.7% | $3.00 | $3.06 | $2.71 | 11,853 | |
| $2.95 | -0.25 | -7.8% | $3.20 | $3.20 | $2.90 | 8,629 | |
| $3.20 | -0.40 | -11.1% | $3.60 | $3.60 | $3.20 | 4,209 | |
| $3.60 | -0.02 | -0.6% | $3.65 | $3.65 | $2.96 | 12,213 | |
| $3.62 | -0.28 | -7.2% | $3.93 | $3.93 | $3.54 | 8,536 | |
| $3.90 | -0.35 | -8.2% | $4.30 | $4.30 | $3.90 | 2,023 | |
| $4.25 | -0.15 | -3.4% | $4.36 | $4.36 | $4.25 | 917 | |
| $4.40 | -0.10 | -2.2% | $4.50 | $4.50 | $4.40 | 2,306 | |
| $4.50 | -0.13 | -2.8% | $4.60 | $4.64 | $4.50 | 938 | |
| $4.63 | -0.12 | -2.5% | $4.81 | $4.85 | $4.63 | 1,928 | |
| $4.75 | 0.00 | 0.0% | $4.75 | $4.75 | $4.70 | 4,080 | |
| $4.75 | +0.05 | +1.1% | $4.66 | $4.75 | $4.66 | 1,045 | |
| $4.70 | -0.04 | -0.8% | $4.84 | $5.00 | $4.67 | 5,486 | |
| $4.74 | +0.19 | +4.2% | $4.61 | $4.75 | $4.61 | 2,400 | |
| $4.55 | +0.07 | +1.6% | $4.50 | $4.63 | $4.45 | 6,747 | |
| $4.48 | -0.52 | -10.4% | $4.78 | $4.78 | $4.35 | 9,541 | |
| $5.00 | -0.70 | -12.3% | $5.50 | $5.50 | $4.87 | 8,440 | |
| $5.70 | -0.09 | -1.6% | $5.83 | $5.85 | $5.70 | 4,611 | |
| $5.79 | -0.015 | -0.3% | $5.81 | $5.95 | $5.79 | 1,690 | |
| $5.805 | -0.095 | -1.6% | $5.95 | $5.95 | $5.74 | 4,080 | |
| $5.90 | -0.40 | -6.3% | $6.30 | $6.30 | $5.85 | 2,734 | |
| $6.30 | -0.10 | -1.6% | $6.40 | $6.40 | $6.01 | 2,812 | |
| $6.40 | -0.15 | -2.3% | $6.61 | $6.61 | $6.40 | 1,181 | |
| $6.55 | -0.20 | -3.0% | $6.84 | $6.84 | $6.55 | 2,251 | |
| $6.75 | -0.01 | -0.1% | $6.90 | $6.90 | $6.75 | 2,052 | |
| $6.76 | -0.09 | -1.3% | $6.92 | $6.92 | $6.65 | 4,800 | |
| $6.85 | 0.00 | 0.0% | $6.92 | $6.93 | $6.80 | 2,022 | |
| $6.85 | +0.03 | +0.4% | $6.98 | $6.98 | $6.85 | 1,107 | |
| $6.82 | -0.19 | -2.7% | $7.07 | $7.07 | $6.79 | 1,800 | |
| $7.01 | -0.04 | -0.6% | $7.07 | $7.20 | $7.01 | 1,740 | |
| $7.05 | +0.24 | +3.5% | $6.85 | $7.10 | $6.85 | 6,725 | |
| $6.81 | -0.13 | -1.9% | $6.96 | $6.96 | $6.76 | 4,356 | |
| $6.94 | +0.01 | +0.1% | $6.81 | $6.94 | $6.61 | 3,160 | |
| $6.93 | +0.03 | +0.4% | $7.00 | $7.00 | $6.78 | 4,639 | |
| $6.90 | -0.30 | -4.2% | $7.06 | $7.08 | $6.75 | 13,060 | |
| $7.20 | +0.60 | +9.1% | $6.58 | $7.20 | $6.29 | 19,298 | |
| $6.60 | +0.49 | +8.0% | $6.19 | $6.60 | $6.19 | 7,331 | |
| $6.11 | -0.09 | -1.5% | $6.27 | $6.40 | $6.11 | 2,905 | |
| $6.20 | +0.15 | +2.5% | $6.05 | $6.34 | $5.80 | 4,420 | |
| $6.05 | -0.51 | -7.8% | $6.74 | $6.77 | $6.05 | 10,112 | |
| $6.56 | -0.07 | -1.1% | $6.80 | $6.80 | $6.50 | 5,872 | |
| $6.63 | -0.01 | -0.2% | $6.68 | $6.68 | $6.63 | 856 | |
| $6.64 | +0.12 | +1.8% | $6.65 | $6.65 | $6.62 | 312 | |
| $6.52 | -0.28 | -4.1% | $6.85 | $6.85 | $6.51 | 7,204 | |
| $6.80 | +0.10 | +1.5% | $6.82 | $6.82 | $6.71 | 1,700 | |
| $6.70 | -0.15 | -2.2% | $6.91 | $6.91 | $6.70 | 1,431 | |
| $6.85 | -0.01 | -0.1% | $6.90 | $6.90 | $6.85 | 300 | |
| $6.86 | +0.08 | +1.2% | $6.80 | $6.86 | $6.71 | 5,805 | |
| $6.78 | -0.05 | -0.7% | $6.83 | $6.85 | $6.77 | 1,700 | |
| $6.83 | +0.10 | +1.5% | $6.91 | $6.91 | $6.83 | 500 | |
| $6.73 | -0.09 | -1.3% | $6.94 | $6.94 | $6.73 | 2,900 | |
| $6.82 | +0.15 | +2.2% | $6.75 | $6.95 | $6.70 | 11,933 | |
| $6.67 | +0.04 | +0.6% | $6.74 | $6.74 | $6.60 | 1,200 |
Splits
1 split · CSE:OPTI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- CSE:OPTI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- CSE
- Currency
- CAD
What changed lately
Latest news release · Nov 18, 2026
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 16 slides
Latest news
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
Nov 18, 2026
Closed $2.61 (-13.0%) on Nov 18, 2026
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
Oct 26, 2026
Closed $4.40 (-2.2%) on Oct 26, 2026
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Oct 20, 2026
Closed $4.75 (+1.1%) on Oct 20, 2026
Optimi Health to Present at the ThinkEquity Conference
Oct 7, 2026
Closed $5.81 (-1.6%) on Oct 7, 2026
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Sep 16, 2026
Closed $6.90 (-4.2%) on Sep 16, 2026
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $6.56 (-1.1%) on Sep 8, 2026
Optimi Health Establishes Discretionary Equity Facility
Aug 14, 2026
Closed $6.60 (-0.8%) on Aug 17, 2026
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 29, 2026
Closed $6.35 (+6.7%) on Jun 29, 2026
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 16, 2026
Closed $5.90 (-14.4%) on Jun 16, 2026
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Jun 10, 2026
Closed $6.55 (-3.0%) on Jun 10, 2026
Optimi Health Corp. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 31 in the last 12 months · 38 in all · newest Nov 18, 2026 · oldest 2025
- Decks
- 7 decks · latest November 2026
Where Optimi Health Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:OPTI · Home listing · This page | CSE | Canada | CAD |
| NASDAQ:OPTH | NASDAQ | United States | USD |
| Cboe Canada:OPTI | Cboe Canada | Canada | CAD |
| gettex:8BN | gettex | Germany | EUR |
| Lang & Schwarz:A2QQEL | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2QQEL | LS Exchange | Germany | EUR |
| BOATS:OPTH | BOATS | United States | USD |
| Frankfurt:8BN0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A411WC | Lang & Schwarz | Germany | EUR |
| LS Exchange:A411WC | LS Exchange | Germany | EUR |
| gettex:8BN0 | gettex | Germany | EUR |
| Hamburg:8BN0 | Hamburg | Germany | EUR |
| Munich:8BN0 | Munich | Germany | EUR |
| Stuttgart:8BN | Stuttgart | Germany | EUR |
| Stuttgart:8BN0 | Stuttgart | Germany | EUR |
| Tradegate:8BN0 | Tradegate | Germany | EUR |
Valuation
EV/sales 0.6× against a median of 0.7×: 5th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $96,161 CAD
- P/E
- Loss
- EV/sales
- 0.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- −175.4%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 1.08
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Optimi Health Corp. · CSE:OPTI | US$9.18M | US$67,058 | n/a | 0.6× | n/a | 0.8× | n/a | 0.0× | 1.08 |
| Bal Pharma Limited · NSE:BALPHARMA | US$14.30M | US$14.30M | 18.4× | 0.4× | 3.9× | 1.6× | 2.1% | 0.0× | n/a |
| Daesung Microbiological Laboratories Co., Ltd. · KRX:036480 | US$14.23M | US$18.69M | 54.3× | 1.0× | 13.5× | 0.6× | 1.4% | 0.4× | n/a |
| Turk Ilac ve Serum Sanayi AS · BIST:TRILC | US$14.16M | US$22.15M | 7.7× | 0.2× | 0.6× | 0.4× | 1.6% | 0.2× | n/a |
| PT Phapros Tbk · IDX:PEHA | US$12.79M | US$41.58M | 4.5× | 0.7× | 4.6× | 0.5× | 5.0% | 1.5× | n/a |
| PT Ikapharmindo Putramas Tbk · IDX:IKPM | US$11.81M | US$10.76M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Alpa Laboratories Limited · NSE:ALPA | US$11.33M | US$11.33M | 24.0× | 0.9× | 12.2× | 0.6× | 3.8% | 0.0× | n/a |
| Advicenne SA · EURONEXT:ALDVI | US$10.53M | US$32.08M | n/a | 4.9× | n/a | n/a | −158.7% | n/a | n/a |
| Biofrontera Inc. · NASDAQ:BFRI | US$9.51M | US$13.83M | n/a | 0.3× | n/a | n/a | −12.7% | n/a | 1.96 |
| ChoA Pharmaceutical Co., Ltd. · KRX:034940 | US$6.59M | US$6.89M | n/a | 0.1× | n/a | 0.3× | −4.6% | 0.1× | n/a |
| Newbury Pharmaceuticals AB · OMXSTO:NEWBRY | US$5.78M | US$4.87M | n/a | 1.2× | n/a | 3.0× | −53.7% | 0.0× | n/a |
| Median of the others | US$11.57M | US$14.06M | 18.4× | 0.7× | 4.6× | 0.6× | 1.4% | 0.0× | 1.96 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.00 CAD · Analysts' mean
- EPS, year to Sep 2026
- -1.42 · 1 analyst
- Revenue, year to Sep 2026
- 665.7K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Dane Stevens | Director — Chief Executive Officer & Co-Founder |
| Jacob Safarik | Chief Financial Officer & Director |
| Bryan Safarik | Chief Operating Officer & Director |
| Karina Lahnakoski | Director of Quality and Commercial Strategies |
| Michael Blough | Chief Clinical Development Officer |
| Preston Chase | Chief Science Officer |
Board
| Director | Role |
|---|---|
| JJ Wilson | Chairman of the Board |
| Bryan Safarik | Chief Operating Officer & Director |
| Dane Stevens | Director — Chief Executive Officer & Co-Founder |
| Jacob Safarik | Chief Financial Officer & Director |
| Jason Mosberian | Independent Director |
| John James Wilson | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 14, 2026 · After close | −0.8% |
| Q2 2026 | Jun 1, 2026 · After close | +2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 16 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 22 slides | September 2026 |
| Investor Presentation (August 2024) | Investor deck | 22 slides | August 2024 |
| Investor Presentation (November 2022) | Investor deck | 28 slides | November 2022 |
| Investor Presentation (January 2022) | Investor deck | 23 slides | January 2022 |
| Investor Presentation (November 2021) | Investor deck | 23 slides | November 2021 |
| IPO Roadshow (January 2021) | IPO roadshow | 22 slides | Jan 15, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Common shares (equity line of credit) Announced: up to US$100M · Joseph Gunnar & Co. LLC Dealers: Joseph Gunnar & Co. LLC (lead) Buyers: Seven Knots, LLC (up to US$100 million of common shares from time to time under the ELOC) | Aug 14, 2026 | |
| Public offering of common shares Update: Joseph Gunnar & Co., LLC Dealers: Joseph Gunnar & Co., LLC (lead) | Apr 23, 2026 | |
| Public offering of common shares Announced: Titan Partners Group, a division of American Capital Partners Dealers: Titan Partners Group, a division of American Capital Partners (lead) | Sep 8, 2025 | |
| Private placement of unsecured convertible debentures Announced: C$3.45M · C$1,000 Buyers: Dane Stevens (Following the acquisition holds 11,875,566 Common Shares or 12.29% of the Company); JJ Wilson (Following the acquisition holds 8,237,501 Common Shares or 8.52% of the Company) Insiders: The Investors are Dane Stevens, CEO, CMO and a director, and JJ Wilson, Chair of the Board and a director; a related party transaction under MI 61-101 Use of proceeds: General working capital | Jul 18, 2025 | US$2.51M |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.25 a share on May 19, 2026.
- Price
- US$6.25 a share
- Shares offered
- 2,400,000 common shares
- Offering size
- US$15 million
- Underwriters' option
- Up to 360,000 more shares
- Listing
- OPTH on the Nasdaq Capital Market
- Underwriter
- Joseph Gunnar & Co., LLC
- Shares delivered
- On or about May 21, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 16, 2025 |
| Filed publicly | Sep 5, 2025 |
| Amended 8 times | Newest May 19, 2026 |
| Shares registered with an exchange | May 19, 2026 |
| Declared effective by the SEC | May 19, 2026 |
| Final prospectus, with the price | May 20, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 20, 2026 |
| EFFECT · Notice that a registration is effective | May 19, 2026 |
| CERT · Exchange's certificate of listing | May 19, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | May 19, 2026 |
| F-1/A · Registration statement, amended | May 19, 2026 |
| F-1/A · Registration statement, amended | Apr 23, 2026 |
| F-1/A · Registration statement, amended | Apr 21, 2026 |
| F-1/A · Registration statement, amended | Apr 21, 2026 |
| F-1/A · Registration statement, amended | Apr 16, 2026 |
| F-1/A · Registration statement, amended | Mar 24, 2026 |
All 15 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Mar 13, 2026 |
| F-1/A · Registration statement, amended | Feb 17, 2026 |
| F-1 · Registration statement | Sep 5, 2025 |
| DRS/A · Draft registration statement, amended | Aug 8, 2025 |
| DRS · Draft registration statement | Jun 16, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed May 20, 2026
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 426.3K | 389.9K | 181.1K | 80.7K | 0 | |
| Cost of revenue | 494.4K | 118.9K | -19.1K | 26.8K | 0 | |
| Gross profit | -68.1K | 270.9K | 200.2K | 53.9K | 0 | |
| Research and development | 347.7K | 387.6K | 152.1K | 133.2K | 240.9K | |
| Selling, general and administrative | 2.72M | 3.85M | 3.82M | 7.02M | 5.77M | |
| Operating income | -4.61M | -5.61M | -5.27M | -7.39M | -6.06M | |
| Depreciation and amortization | 950.3K | 867.9K | 729.6K | 293.6K | 47.1K | 16.3K |
| EBITDA | -3.66M | -4.74M | -4.54M | -7.10M | -6.01M | |
| Interest expense | 531.7K | 429.3K | 43.7K | 28.0K | 19.2K | 0 |
| Income before tax | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M | |
| Net income | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M | |
| Earnings per share, basic | -1.15 | -1.91 | -0.06 | -0.09 | -0.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.15M | 103.7K | 1.34M | 1.89M | 8.43M | 4.47M |
| Short-term investments | 0 | 4.00M | 0 | |||
| Receivables | 95.1K | 124.1K | 165.7K | 98.7K | 188.2K | 83.2K |
| Inventory | 310.4K | 894.8K | 779.3K | 264.7K | 123.2K | |
| Current assets | 1.83M | 1.23M | 2.43M | 2.43M | 14.3M | 4.62M |
| Property, plant and equipment | 14.4M | 8.90M | 1.52M | |||
| Total assets | 15.2M | 14.6M | 16.5M | 16.8M | 23.5M | 6.17M |
| Accounts payable | 1.19M | 749.4K | 901.9K | 556.0K | 2.11M | 647.3K |
| Current liabilities | 8.48M | 3.22M | 1.61M | 728.2K | 2.24M | 751.8K |
| Long-term debt | 1.76M | 1.64M | ||||
| Total liabilities | 8.64M | 4.98M | 3.28M | 797.7K | 2.40M | 882.7K |
| Shareholders' equity | 6.57M | 9.58M | 13.2M | 16.0M | 21.1M | 5.29M |
| Shares outstanding | 3.22M | 3.16M | 87.0M | 80.9M | 69.9M | 69.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M | -422.4K |
| Capital spending | -88.4K | -152.4K | -804.2K | -7.15M | -4.94M | -2.26M |
| Free cash flow | -2.72M | -4.43M | -4.41M | -11.7M | -11.0M | -2.69M |
| Cash from investing | -3.15M | -9.19M | -2.26M | |||
| Cash from financing | 3.76M | 3.19M | 3.76M | 1.19M | 19.2M | 16.1M |
| Change in cash | 1.04M | -1.24M | -543.8K | -6.54M | 3.96M | 13.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 5, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 23, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 22, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 10, 2026 | Current report | SEC |
All 48 filings
Cap table
Built by 6ix from Optimi Health Corp.’s releases · as of Aug 14, 2026
- Common shares
- 5,725,867
- Fully diluted
- 5,725,867
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 5,725,867 | Jun 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Jun 30, 2026 | 5,725,867 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bryan Safarik | Chief Operating Officer & Director · Since at least Nov 5, 2026 |
| Dane Stevens | Director — Chief Executive Officer & Co-Founder · Since at least Oct 26, 2026 |
| Jacob Safarik | Chief Financial Officer & Director · Since at least Nov 5, 2026 |
| Jason Mosberian | Independent Director · Since at least Dec 18, 2025 |
| JJ Wilson | Chairman of the Board · Since at least Mar 16, 2026 |
| John James Wilson | Director · Since at least Nov 5, 2026 |
| Karina Lahnakoski | Director of Quality and Commercial Strategies · Since at least Nov 5, 2026 |
| Michael Blough | Chief Clinical Development Officer · Since at least Nov 5, 2026 |
| Preston Chase | Chief Science Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Optimi Health Corp.